Profile data is unavailable for this security.
About the company
BSF Enterprise PLC is a United Kingdom-based biotechnology company. The Company is focused on developing biotechnological solutions using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes. The Company operates through its wholly owned subsidiary, 3D Bio-Tissues Limited (3DBT), which is a clinical and cellular agriculture company engaged in producing human corneas that could help restore vision to millions of people. 3DBT has three strands of three intellectual property (IP) each with a different sector focus development and revenue timeline. 3DBT’s City-mix is an animal-free cell growth agent for culturing skin, muscle and fat cells which are used for lab-grown meat and leather production. 3DBT’s Lipopeptide Etsyl actively increases collagen production in human skin cells which can be used in cosmetic and skin care products.
- Revenue in GBP (TTM)67.24k
- Net income in GBP-1.71m
- Incorporated2018
- Employees4.00
- LocationBSF Enterprise PLCGround Floor, 31 Old Burlington StreetLONDON W1S 3ASUnited KingdomGBR
- Phone+44 203 283 4590
- Websitehttps://bsfenterprise.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nuformix PLC | 0.00 | -341.86k | 1.43m | 2.00 | -- | 0.3495 | -- | -- | -0.0005 | -0.0005 | 0.00 | 0.005 | 0.00 | -- | -- | -- | -7.72 | -- | -8.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
N4 Pharma PLC | 1.95k | -1.28m | 1.68m | 5.00 | -- | 1.01 | -- | 860.42 | -0.0053 | -0.0053 | 0.00001 | 0.0042 | 0.0011 | -- | 0.009 | 390.00 | -74.20 | -57.05 | -79.41 | -61.13 | -- | -- | -65,475.90 | -309,312.80 | -- | -- | 0.00 | -- | -- | -51.52 | -24.05 | -- | -- | -- |
BSF Enterprise PLC | 67.24k | -1.71m | 4.91m | 4.00 | -- | 1.23 | -- | 73.00 | -0.0166 | -0.0166 | 0.0007 | 0.0387 | 0.0128 | 1.79 | 0.0425 | 16,810.00 | -32.47 | -- | -34.78 | -- | -44.74 | -- | -2,542.56 | -- | 6.17 | -218.85 | 0.0287 | -- | -- | -- | -61.40 | -- | -- | -- |
CRISM' Therapeutics Corp | 0.00 | -1.87m | 5.13m | 4.00 | -- | 0.4241 | -- | -- | -0.2146 | -0.8659 | 0.00 | 0.3699 | 0.00 | -- | -- | 0.00 | -14.26 | -8.67 | -14.89 | -9.02 | -- | -- | -- | -- | -- | -3.51 | 0.00 | -- | -- | -- | 8.21 | -- | -- | -- |
Oncimmune Holdings PLC | 1.21m | -3.19m | 7.30m | 56.00 | -- | -- | -- | 6.02 | -0.0427 | 0.0939 | 0.0163 | -0.0172 | 0.1756 | 1.19 | 0.6917 | -- | -46.21 | -- | -- | -- | 63.34 | -- | -263.10 | -- | 1.01 | -0.6815 | 1.32 | -- | -- | -- | -- | -- | -- | -- |
Kanabo Group PLC | 895.00k | -7.99m | 8.85m | 17.00 | -- | 1.18 | -- | 9.89 | -0.0137 | -0.0137 | 0.0017 | 0.0119 | 0.0785 | 11.11 | 28.41 | 52,647.06 | -70.12 | -75.83 | -77.61 | -83.33 | 14.97 | -- | -893.30 | -1,267.35 | 4.96 | -10.43 | 0.035 | -- | 48.42 | -- | -16.26 | -- | -- | -- |